Halozyme Therapeutics Inc (HALO):企業の財務・戦略的SWOT分析

◆英語タイトル:Halozyme Therapeutics Inc (HALO) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1663
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,125見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,375見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Halozyme Therapeutics Inc (HALO) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes for enhancing the delivery of biologics and drugs. The company’s marketed product, Hylenex, is a branded, recombinant formulation of rHuPH20, which enables administration of subcutaneous fluid with improved hydration, absorption and dispersion of other injected drugs and also with an enhanced resorption of radiopaque agents in subcutaneous urography. It also offers proprietary Enhanze, a drug-delivery technology built on its patented recombinant human hyaluronidase enzyme, rHuPH20. The company works in partnership with Pfizer, Roche, Baxalta, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and Argenx for advancing treatment for various cancer types. Halozyme is headquartered in San Diego, California, the US.

Halozyme Therapeutics Inc Key Recent Developments

Feb 24,2020 Halozyme announces CFO transition
Feb 24,2020 Halozyme reports fourth quarter and full year 2019 results
Jan 14,2020 Halozyme provides 2020 business update and financial guidance
Nov 12,2019 Halozyme reports third quarter 2019 results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Halozyme Therapeutics Inc – Key Facts
Halozyme Therapeutics Inc – Key Employees
Halozyme Therapeutics Inc – Key Employee Biographies
Halozyme Therapeutics Inc – Major Products and Services
Halozyme Therapeutics Inc – History
Halozyme Therapeutics Inc – Company Statement
Halozyme Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Halozyme Therapeutics Inc – Business Description
Product Category: Net Product Sales
Performance
Product Category: Revenue Under Collaborative Agreements
Performance
Product Category: Royalties
Performance
Geographical Segment: All Other Foreign
Performance
Geographical Segment: Switzerland
Performance
Geographical Segment: The US
Performance
R&D Overview
Halozyme Therapeutics Inc – Corporate Strategy
Halozyme Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Halozyme Therapeutics Inc – Strengths
Halozyme Therapeutics Inc – Weaknesses
Halozyme Therapeutics Inc – Opportunities
Halozyme Therapeutics Inc – Threats
Halozyme Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Halozyme Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 24, 2020: Halozyme announces CFO transition
Feb 24, 2020: Halozyme reports fourth quarter and full year 2019 results
Jan 14, 2020: Halozyme provides 2020 business update and financial guidance
Nov 12, 2019: Halozyme reports third quarter 2019 results
Nov 04, 2019: Halozyme announces actions to focus strategy on ENHANZE drug delivery technology
Aug 06, 2019: Halozyme reports second quarter 2019 results
May 06, 2019: Halozyme names Dr. Alison A. Armour as Senior Vice President Of Research And Development
Feb 21, 2019: Halozyme Reports Fourth Quarter And Full-Year 2018 Results
Feb 05, 2019: Argenx to leverage Halozyme’s subcutaneous drug delivery technology
Jan 09, 2019: Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Halozyme Therapeutics Inc, Key Facts
Halozyme Therapeutics Inc, Key Employees
Halozyme Therapeutics Inc, Key Employee Biographies
Halozyme Therapeutics Inc, Major Products and Services
Halozyme Therapeutics Inc, History
Halozyme Therapeutics Inc, Subsidiaries
Halozyme Therapeutics Inc, Key Competitors
Halozyme Therapeutics Inc, Ratios based on current share price
Halozyme Therapeutics Inc, Annual Ratios
Halozyme Therapeutics Inc, Annual Ratios (Cont...1)
Halozyme Therapeutics Inc, Annual Ratios (Cont...2)
Halozyme Therapeutics Inc, Interim Ratios
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Halozyme Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Halozyme Therapeutics Inc, Performance Chart (2015 - 2019)
Halozyme Therapeutics Inc, Ratio Charts
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Halozyme Therapeutics Inc (HALO):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Phillips 66 Co (PSX):石油・ガス:M&Aディール及び事業提携情報
    Summary Phillips 66 Co (Phillips 66) is a diversified energy manufacturing and logistics company. It gathers, processes, transports, stores and markets natural gas and petroleum products such as gasoline, diesel, aviation fuel and lubricants. It also transports, fractionates and markets natural gas …
  • John Menzies Plc:企業の戦略・SWOT・財務分析
    John Menzies Plc - Strategy, SWOT and Corporate Finance Report Summary John Menzies Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Compania Minera Antamina SA:企業の戦略・SWOT・財務情報
    Compania Minera Antamina SA - Strategy, SWOT and Corporate Finance Report Summary Compania Minera Antamina SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • YTL Corporation Berhad:企業の戦略・SWOT・財務分析
    YTL Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary YTL Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Accu-Break Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Accu-Break Pharmaceuticals Inc (Accu-Break) is a developer and provider of pharmaceutical tablet technologies for accurate and customized dosing. The company provides services such as patented technologies, product differentiation, life cycle management, APIs solutions, product enhancement, …
  • Hatch Ltd:企業の戦略的SWOT分析
    Hatch Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Olin Corporation
    Olin Corporation - Strategy, SWOT and Corporate Finance Report Summary Olin Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Zymeworks Inc (ZYME):製薬・医療:M&Aディール及び事業提携情報
    Summary Zymeworks Inc (Zymeworks) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of biotherapeutics for the treatment of cancer, autoimmune and inflammatory diseases. Its pipeline products include ZW25 and ZW49, novel bispecific antibodies …
  • L’Oreal SA:企業のM&A・事業提携・投資動向
    L'Oreal SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's L'Oreal SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • NeuStar Inc:企業の戦略的SWOT分析
    NeuStar Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Armada Hoffler Properties Inc:企業の戦略・SWOT・財務分析
    Armada Hoffler Properties Inc - Strategy, SWOT and Corporate Finance Report Summary Armada Hoffler Properties Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Warpaint London plc (W7L):企業の財務・戦略的SWOT分析
    Warpaint London plc (W7L) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Kmart Corporation:企業の戦略的SWOT分析
    Kmart Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • BASF Corp:企業の戦略的SWOT分析
    BASF Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Huesker Synthetic Gmbh:企業の戦略・SWOT・財務分析
    Huesker Synthetic Gmbh - Strategy, SWOT and Corporate Finance Report Summary Huesker Synthetic Gmbh - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Tom N Toms Holdings Co., Ltd.:企業の戦略・SWOT・財務分析
    Tom N Toms Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tom N Toms Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • CryoLife Inc (CRY)-医療機器分野:企業M&A・提携分析
    Summary CryoLife Inc (CryoLife) is a provider of biosurgical devices and implantable living tissues for cardiac and vascular surgical procedures. The company’s portfolio encompasses preserved human cardiac allografts, vascular allografts, surgical adhesives and sealants, heart valves, carbon dioxide …
  • USV Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary USV Pvt Ltd (USV) is a healthcare company that offers pharmaceutical products. The company’s products include active pharmaceutical ingredients, biosimilars, injectables, ophthalmics, peptides and solid orals. Its biosimilars products comprise PEG-filgrastim, teriparatide, somatropin, filgra …
  • Taiflex Scientific Co., Ltd. (8039):企業の財務・戦略的SWOT分析
    Taiflex Scientific Co., Ltd. (8039) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Cantargia AB (CANTA):企業の財務・戦略的SWOT分析
    Summary Cantargia AB (Cantargia), a subsidiary of Lund University Bioscience AB is a biotechnology company that develops antibody based cancer treatments. The company’s product candidate CAN04 is used for the treatment of several cancers including non-small cell lung cancer and pancreatic cancer. It …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆